⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 16, 2024Antimicrobial Agents and ChemotherapyOpen Access

A phase 1 open label study to assess the human mass balance and metabolite profile of ¹⁴ C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participants

Michael R. Hodges Eric Ople Philip Evans A.J. Pantophlet Jessica Richardson D. T. Williams Sakambari Tripathy Margaret Tawadrous Abhijeet Jakate

View Full Paper

Ask AI

Bookmark

Share

Abstract

Fosmanogepix [FMGX; active form manogepix (MGX)], a novel antifungal, is currently being studied for the treatment of invasive fungal diseases caused by

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hodges et al. (2024) studied this question.

synapsesocial.com/papers/68e6023bb6db64358759580c https://doi.org/10.1128/aac.00273-24

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants2024 · 10 citations
2Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants2024 · 12 citations
3Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials2024 · 22 citations
4Clinical Efficacy and Safety of Fosmanogepix in Patients with Invasive and Refractory Fungal Infections: A Systematic ReviewSystematic Review · 2026
5Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 TrialHuman Clinical Trial · 2023 · 89 citations